Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
NCT07574528Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Therapeutic Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, pegaspargase, selinexor in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Planned start May 2026; status: not yet recruiting.
02
Drugs
sintilimabpegaspargaseselinexor
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07574528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574528.